David Amsellem
Stock Analyst at Piper Sandler
(4.82)
# 94
Out of 5,147 analysts
164
Total ratings
66.17%
Success rate
23.97%
Average return
Main Sectors:
Stocks Rated by David Amsellem
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PTHS Pelthos Therapeutics | Initiates: Overweight | $48 | $26.36 | +82.09% | 1 | Feb 27, 2026 | |
| BMY Bristol-Myers Squibb Company | Maintains: Overweight | $66 → $75 | $62.37 | +20.25% | 3 | Feb 23, 2026 | |
| AMGN Amgen | Maintains: Overweight | $381 → $432 | $388.16 | +11.29% | 7 | Feb 18, 2026 | |
| ABBV AbbVie | Maintains: Overweight | $289 → $299 | $232.08 | +28.83% | 4 | Feb 18, 2026 | |
| BIIB Biogen | Maintains: Neutral | $157 → $177 | $191.82 | -7.73% | 4 | Feb 9, 2026 | |
| VTRS Viatris | Maintains: Neutral | $9 → $12 | $14.93 | -19.62% | 8 | Jan 28, 2026 | |
| AXSM Axsome Therapeutics | Maintains: Overweight | $148 → $223 | $163.89 | +36.07% | 4 | Jan 16, 2026 | |
| FENC Fennec Pharmaceuticals | Initiates: Overweight | $18 | $8.49 | +112.01% | 1 | Jan 9, 2026 | |
| TEVA Teva Pharmaceutical Industries | Maintains: Overweight | $30 → $40 | $33.86 | +18.13% | 11 | Dec 22, 2025 | |
| JAZZ Jazz Pharmaceuticals | Reiterates: Overweight | $147 → $219 | $190.02 | +15.25% | 15 | Dec 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $3.35 | +168.66% | 1 | Nov 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $8 | $4.00 | +100.00% | 2 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $6 → $8 | $6.12 | +30.72% | 6 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $11 → $13 | $13.81 | -5.87% | 5 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $175 → $179 | $132.25 | +35.35% | 12 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $38 → $45 | $30.10 | +49.50% | 8 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $40 → $65 | $54.73 | +18.76% | 17 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $30 → $25 | $20.23 | +23.58% | 9 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $131 → $121 | $35.70 | +238.94% | 8 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $24 → $18 | $7.29 | +146.91% | 6 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $36 → $37 | $41.67 | -11.21% | 8 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $68 | $73.90 | -7.98% | 1 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $9 → $3 | $5.93 | -49.41% | 7 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 | $21.91 | +91.69% | 10 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $21 | $3.42 | +514.04% | 3 | Feb 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $72 → $42 | $28.54 | +47.16% | 3 | Oct 16, 2023 |
Pelthos Therapeutics
Feb 27, 2026
Initiates: Overweight
Price Target: $48
Current: $26.36
Upside: +82.09%
Bristol-Myers Squibb Company
Feb 23, 2026
Maintains: Overweight
Price Target: $66 → $75
Current: $62.37
Upside: +20.25%
Amgen
Feb 18, 2026
Maintains: Overweight
Price Target: $381 → $432
Current: $388.16
Upside: +11.29%
AbbVie
Feb 18, 2026
Maintains: Overweight
Price Target: $289 → $299
Current: $232.08
Upside: +28.83%
Biogen
Feb 9, 2026
Maintains: Neutral
Price Target: $157 → $177
Current: $191.82
Upside: -7.73%
Viatris
Jan 28, 2026
Maintains: Neutral
Price Target: $9 → $12
Current: $14.93
Upside: -19.62%
Axsome Therapeutics
Jan 16, 2026
Maintains: Overweight
Price Target: $148 → $223
Current: $163.89
Upside: +36.07%
Fennec Pharmaceuticals
Jan 9, 2026
Initiates: Overweight
Price Target: $18
Current: $8.49
Upside: +112.01%
Teva Pharmaceutical Industries
Dec 22, 2025
Maintains: Overweight
Price Target: $30 → $40
Current: $33.86
Upside: +18.13%
Jazz Pharmaceuticals
Dec 10, 2025
Reiterates: Overweight
Price Target: $147 → $219
Current: $190.02
Upside: +15.25%
Nov 25, 2025
Initiates: Overweight
Price Target: $9
Current: $3.35
Upside: +168.66%
Nov 7, 2025
Maintains: Overweight
Price Target: $5 → $8
Current: $4.00
Upside: +100.00%
Nov 7, 2025
Maintains: Neutral
Price Target: $6 → $8
Current: $6.12
Upside: +30.72%
Oct 31, 2025
Reiterates: Overweight
Price Target: $11 → $13
Current: $13.81
Upside: -5.87%
Oct 29, 2025
Maintains: Overweight
Price Target: $175 → $179
Current: $132.25
Upside: +35.35%
Oct 23, 2025
Reiterates: Overweight
Price Target: $38 → $45
Current: $30.10
Upside: +49.50%
Oct 9, 2025
Upgrades: Overweight
Price Target: $40 → $65
Current: $54.73
Upside: +18.76%
Aug 8, 2025
Maintains: Neutral
Price Target: $30 → $25
Current: $20.23
Upside: +23.58%
Aug 1, 2025
Maintains: Overweight
Price Target: $131 → $121
Current: $35.70
Upside: +238.94%
May 15, 2025
Maintains: Overweight
Price Target: $24 → $18
Current: $7.29
Upside: +146.91%
May 9, 2025
Reiterates: Neutral
Price Target: $36 → $37
Current: $41.67
Upside: -11.21%
Oct 11, 2024
Initiates: Overweight
Price Target: $68
Current: $73.90
Upside: -7.98%
Aug 2, 2024
Downgrades: Underweight
Price Target: $9 → $3
Current: $5.93
Upside: -49.41%
Jul 3, 2024
Maintains: Overweight
Price Target: $42
Current: $21.91
Upside: +91.69%
Feb 16, 2024
Maintains: Overweight
Price Target: $20 → $21
Current: $3.42
Upside: +514.04%
Oct 16, 2023
Maintains: Overweight
Price Target: $72 → $42
Current: $28.54
Upside: +47.16%